PR Newswire PharmaOriginal article
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Data ReadoutpositiveRYBREVANTPositive
AI Analysis
Summary
Johnson & Johnson reported that RYBREVANT (amivantamab-vmjw) plus chemotherapy achieved the longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer, demonstrating durable benefit for a patient population with historically poor outcomes.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
RYBREVANT plus chemotherapy demonstrates longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer with durable benefit
Importance:7/10
Sentiment:
0.85
oncologylung cancerclinical dataEGFR mutationdual targeting
Related Companies
Read the original article
Published by PR Newswire Pharma on September 14, 2026 1:45 AM